Earlier this month, Vivus Inc. (NASDAQ:VVUS) said it filed a patent-infringement lawsuit against Actavis PLC ( ACT ) alleging that the drug maker’s planned generic version of weight-loss drug Qsymia infringes its patents. VIVUS, Inc. (NASDAQ:VVUS) stock performance was 3.97% in last session and finished the day at $5.50. Traded volume was 4.47million shares in the last session and the average volume of the stock remained 3.04million shares. The beta of the stock remained 1.41. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.60%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on June 3 announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -1.62 percent to $6.07 Friday on volume of 4.30million shares. The intra-day range of the stock was $6.02 to $6.22. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a market capitalization of $1.33billion.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that its Annual Meeting of Stockholders will be webcast live on June 25, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on June 20, 2014 reported a increase of 1.37% to the closing price of $6.66. Its fifty two weeks range is $2.15-$23.00. The total market capitalization recorded $1.24billion. The overall volume in the last trading session was 7.70million shares. In its share capital, ARIA has Q86.80million outstanding shares.

MannKind Corporation  (NASDAQ:MNKD) VP Diane Palumbo unloaded 17,902 shares of the company stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $10.59, for a total value of $189,582.18. Following the sale, the vice president now directly owns 140,956 shares of the company’s stock, valued at approximately $1,492,724. On Friday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -1.62% to close the day at $10.35. Company monthly performance is recorded as 32.52%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 76.32%.

Sanofi’s experimental new drug Toujeo is being positioned to succeed Lantus when it loses patent protection early next year. Eli Lilly and Co (NYSE:LLY) is working on a drug similar to Lantus. Eli Lilly and Co (NYSE:LLY) stock performance was 3.64% in last session and finished the day at $62.03. Traded volume was 11.96million shares in the last session and the average volume of the stock remained 4.70million shares. The beta of the stock remained 0.38. Eli Lilly and Co (NYSE:LLY) insider ownership is 12.10%.